The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to address these challenges within the spatial biology space head-on.

Across an intensive 2-day agenda, you’ll explore practical solutions to issues spanning data infrastructure, multi-omics integration, standardization, scalability, and translation into the clinic. This year’s forum will equip you with the latest data-driven strategies to not only overcome obstacles but to maximize the value of spatial biology for deeper disease insights, robust target identification, biomarker discovery, and more.

Find out more here: https://ter.li/otrpyk

Spatial biology is at a turning point. Rapid advances in resolution, sensitivity, and multi-omics integration are delivering more robust and clinically meaningful insights than ever before. Recent collaborations and investments, such as GSK’s partnership with Relation Therapeutics and Sanofi’s expanded partnership with Owkin, highlight the strong momentum and confidence building across the sector. Yet, challenges around data standardization, integration, scalability, and cost continue to limit widespread adoption, particularly among small and mid-sized biopharma companies.

No other meeting will give you the chance to connect with 70+ spatial biology experts for *free and take away fresh, actionable data from AstraZeneca, Takeda, AbbVie, Genentech, Amgen, Pfizer, Johnson & Johnson, and many more – the exact people you need to meet to move your work forward.

Join the spatial biology community (for free) here: https://ter.li/fvnrcc